Prevalence and estimation of hepatitis B and C infections in the WHO European Region: A review of data focusing on the countries outside the European Union and the European Free Trade Association

Epidemiology and Infection

Volumn 142, Issue 2, 2014, Pages 270-286

  Hope, V D ^a,b   Eramova, I ^c   Capurro, D ^c   Donoghoe, M C ^c  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

Author keywords

Epidemiology; European Region; hepatitis B; hepatitis C; prevalence

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; HEPATITIS C ANTIGEN;

BLOOD DONOR; EUROPE; EUROPEAN FREE TRADE ASSOCIATION; EUROPEAN UNION; HEPATITIS B; HEPATITIS C; HUMAN; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ABUSE; MEN WHO HAVE SEX WITH MEN; PREVALENCE; PROSTITUTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TAJIKISTAN; UKRAINE; UZBEKISTAN; WORLD HEALTH ORGANIZATION; BLOOD; EASTERN EUROPE; FEMALE; MALE; MALE HOMOSEXUALITY; PREGNANCY; STATISTICS AND NUMERICAL DATA;

BLOOD DONORS; EUROPE, EASTERN; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HEPATITIS C ANTIGENS; HOMOSEXUALITY, MALE; HUMANS; MALE; PREGNANCY; PREVALENCE; SEROEPIDEMIOLOGIC STUDIES; SEX WORKERS;

EID: 84894354149     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813000940     Document Type: Review

References (37)

1. WHO. Prevention and control of viral hepatitis infection: frame work for global action 2012. Geneva: WHO, 2012 (www.who.int/csr/disease/hepatitis/GHP- framework.pdf). Accessed 14 December 2012.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004; 11: 97-107.
3. Goldstein ST, et al. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. International Journal of Epidemiology 2005; 34: 1329-39.
4. World Health Organization. Hepatitis C-global prevalence (update). Weekly Epidemiological Record 1999; 74: 425-27.
5. WHO Executive Board. Viral hepatitis. Report by the Secretariat. EB126/15. Geneva: WHO; 12 November 2009: http://apps.who.int/gb/ebwha/pdf-files/ EB126/B126-15-en.pdf.
6. Perz JF, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology 2006; 45: 529-538.
7. European Centre for Disease Prevention and Control. Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. Stockholm: ECDC; September 2010 (www.ecdc. europa.eu/en/publications/ Publications/TER-100914- Hep-B-C%20-EU-neighbourhood.pdf).
8. Platt L, et al. The HIV epidemics of Europe: vulnerability and response. World Bank (in press).
9. Lauer GM, Walker BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 41-52.
10. Munir S, et al. Hepatitis C treatment: current and future perspectives. Virology Journal 2010; 7: 296.
11. Lee WM. Medical progress: hepatitis B virus infection. New England Journal of Medicine 1997; 337: 1733-1745.
12. Hagan H, Des Jarlais DC. HIV and HCV Infection among Injecting Drug Users. Mount Sinai Journal of Medicine 2000; 67: 423-428.
13. Matthews GV, et al. Patterns and characteristics of hepatitis C transmission clusters among HIV-positive and HIV-negative individuals in the Australian Trial in Acute Hepatitis C. Clinical Infectious Diseases 2011; 52: 803-811.
14. Lauer GM, Walker BD. Hepatitis C virus infection. New England Journal of Medicine 2001; 345: 41-52.
15. Sorrell MF, et al. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis B. Annals of Internal Medicine 2009; 150: 104-110.
16. National Institutes of Health. Consensus development conference statement: management of hepatitis C: 2002-10-12 June, 2002. Hepatology 2002; 36: S3-20.
17. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. Journal of Hepatology 2009; 50: 227-242.
18. Ghany MG, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
19. Vickerman P, Martin N, Hickman M. Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug and Alcohol Dependence 2011; 113: 83-85.
20. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl. 1): S35-S46.
21. Toy M, et al. Potential impact of long-term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B. Hepatology 2009; 50: 743-751.
22. Hutton DW, et al. Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Annals of Internal Medicine 2007; 147: 460-469.
23. Directorate for the Quality of Medicines and Health Care of the Council of Europe. The collection, testing and use of blood and blood components in Europe: 2006 Report. Council of Europe Publishing, Strasbourg, 2010.
24. World Health Organization. World Health Statistics 2010. Geneva, World Health Organization, 2010.
25. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. Journal of Viral Hepatitis 2006; 13: 34-41.
26. Mathers B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-1745.
27. EMCDDA. Statistical Bulletin 2010 (www.emcdda. europa.eu/stats10/pdu). Accessed 6 May 2011.
28. Bozicevic I, et al. HIV epidemics among men who have sex with men in central and eastern Europe. Sexually Transmitted Infections 2009; 85: 336-342.
29. Mariano A, et al. Estimating the incidence, prevalence and clinical burden of hepatitis C over time in Italy. Scandinavian Journal of Infectious Diseases 2009; 41: 689-699.
30. Harris R, et al. Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. European Journal of Public Health 2012; 22: 187-192.
31. Scottish Government. Hepatitis C Action Plan for Scotland: Phase II (May 2008-March 2011). Edinburgh: Scottish Government, May 2008 (www. scotland.gov.uk/Resource/Doc/222750/0059978.pdf). Accessed 8 December 2011.
32. European Hepatitis B Expert Group. European orientation towards the better management of hepatitis in Europe. Recommendations of the Hepatitis B expert group, 2008 (www.elpa-info.org/tl-files/elpa- downloads/hep-b.pdf). Accessed 14 December 2012.
33. Jolley E, et al. HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy. British Medical Journal. Published online: 18 October 2012. doi: 10.1136/bmjopen-2012-001465
34. WHA. Sixty-third World Health Assembly: viral hepatitis. WHA63.18. Geneva: WHO, 21 May 2010 (http://apps.who.int/gb/ebwha/pdf-files/WHA63/A63-R18- en. pdf). Accessed 14 December 2012.
35. Brook G, Soriano V, Bergin C. European guideline for the management of hepatitis B and C virus infections, 2010. International Journal of STD & AIDS 2010; 21: 669-678
36. WHO. Hepatitis B vaccines. WHO position paper. Weekly Epidemiological Record 2009; 84, 405-420.
37. WHO Regional Office for Europe. European Action Plan for HIV/AIDS 2012-2015. Copenhagen, WHO Regional Office for Europe, 2011 (www.euro.who.int/ en/what-we-do/health-topics/communicable-diseases/hivaids/publications/2011/ european-action-plan-for-hivaids-20122015). Accessed 8 December 2011.